← Back to Search

Histone Deacetylase Inhibitor

Treatment for Multiple Myeloma (RECOMM Trial)

N/A
Waitlist Available
Research Sponsored by ppharmaand GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Summary

This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Response to treatment

Find a Location

Who is running the clinical trial?

ppharmaand GmbHLead Sponsor
11 Previous Clinical Trials
1,515 Total Patients Enrolled
1 Trials studying Multiple Myeloma
248 Patients Enrolled for Multiple Myeloma
zr Pharma & GmbHLead Sponsor
20 Previous Clinical Trials
3,843 Total Patients Enrolled
1 Trials studying Multiple Myeloma
248 Patients Enrolled for Multiple Myeloma
pharmaand GmbHLead Sponsor
21 Previous Clinical Trials
3,926 Total Patients Enrolled
1 Trials studying Multiple Myeloma
248 Patients Enrolled for Multiple Myeloma
~43 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top